[1]刘娟婧,杨志明.白脂素对代谢性心血管疾病潜在作用的研究进展[J].心血管病学进展,2023,(8):728.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.013]
　LIU Juanjing,YANG Zhiming.Effect of Asprosin on Metabolic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(8):728.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.013]
点击复制

白脂素对代谢性心血管疾病潜在作用的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年8期
页码:
728
栏目:
综述
出版日期:
2023-08-25

文章信息/Info

Title:
Effect of Asprosin on Metabolic Cardiovascular Disease
作者:
刘娟婧1;  杨志明2
(１.山西医科大学,山西 太原 030000 ;2.山西医科大学第二医院心内科,山西 太原 030000 )
Author(s):
LIU Juanjing1; YANG Zhiming2
(1.Shanxi Medical University,Taiyuan 030000 ,Shanxi,China2.Department of Cardiology,Second Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi,China)
关键词:
代谢性心血管疾病; 白脂素; 肥胖; 糖尿病; 非酒精性脂肪性肝病
Keywords:
Metabolic cardiovascular disease; Asprosin; Obesity; Diabetes Mellitus; Non-alcoholic fatty liver disease
DOI:
10.16806/j.cnki.issn.1004-3934.2023.08.013
摘要:
代谢性心血管疾病是主要因糖脂代谢紊乱出现的心血管疾病，目前其发生机制尚未明确，但干预代谢可有效改善预后。目前已知众多脂肪因子参与到心血管疾病的病理机制中，白脂素作为新型脂肪因子能够促进代谢紊乱提高心血管疾病的发病风险，但亦可降低脂质沉积和氧化应激损伤发挥心血管保护作用。现就白脂素在代谢性心血管疾病中的潜在作用进行综述，以期白脂素能为代谢性心血管疾病的防治提供新思路。
Abstract:
Metabolic cardiovascular disease is a cardiovascular disease mainly caused by the disorder of glucose and lipid metabolism. The mechanism of its occurrence has not been clarified yet,but the intervention of metabolism can effectively improve the prognosis. At present,many adipokines are known to be involved in the pathological mechanism of cardiovascular disease. Asprosin ,as a novel adipokine,can promote metabolic disorders and increase the risk of cardiovascular disease.but also play a protective role in cardiovascular disease by reducing oxidative stress and lipidoses. This article reviews the potential role of Asprosin in metabolic cardiovascular disease,hoping that Asprosin can provide new ideas for the prevention,control and treatment of metabolic cardiovascular disease

参考文献/References:

[1] 祝之明. 代谢性心血管病:理念、挑战与实践[J]. 中华心血管病杂志,2021,49(7):650-655.

[2] Arnett DK,Khera A,Blumenthal RS. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease:part 1,lifestyle and behavioral factors[J]. JAMA Cardiol,2019,4(10):1043-1044.

[3] Romere C,Duerrschmid C,Bournat J,et al. Asprosin,a fasting-induced glucogenic protein hormone[J]. Cell,2016,165(3):566-579.

[4] Lee T,Yun S,Jeong JH,et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation[J]. Mol Cell Endocrinol,2019,486:96-104.

[5] Gozel N,Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin[J]. Endokrynol Pol,2021,72(1):37-43.

[6] Kocaman N,Kulo?lu T. Expression of asprosin in rat hepatic,renal,heart,gastric,testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model[J]. Tissue cell,2020,66:101397.

[7] Morcos YAT,Lütke S,Tenbieg A,et al. Sensitive asprosin detection in clinical samples reveals serum/saliva correlation and indicates cartilage as source for serum asprosin[J]. Sci Rep,2022,12(1):1340.

[8] Min YI,Gao Y,Anugu P,et al. Obesity and overall mortality:findings from the jackson heart study[J]. BMC Public Health,2021,21(1):50.

[9] Clemens D,Yanlin H,Chunmei W,et al. Asprosin is a centrally acting orexigenic hormone[J]. Nat Med,2017,23(12).

[10] Miao YL,Qin HJ,Zhong Y,et al. Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue[J]. J Endocrinol,2021,249(2):83-93.

[11] Sünnet?i Silistre E,Hatipo?l H. Increased serum circulating asprosin levels in children with obesity[J]. Pediatr Int,2020,62(4):467-476.

[12] Liu L,Kang Y,Xiao Y. Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity[J]. World J Pediatr,2021,17(4):394-399.

[13] Karampetsou N,Alexopoulos L,Minia A,et al. Epicardial adipose tissue as an independent cardiometabolic risk factor for coronary artery disease[J]. Cureus,2022,14(6):e25578.

[14] Ma H,Zhang G,Mou C,et al. Peripheral CB1 receptor neutral antagonist,AM6545,ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice[J]. Front Pharmacol,2018,9:156.

[15] Elnagar A,El-Dawy K,El-Belbasi HI,et al. Ameliorative Effect of Oxytocin on FBN1 and PEPCK Gene Expression,and Behavioral Patterns in Rats ’ Obesity-Induced Diabetes[J]. Front Public Health,2022,10:777129.

[16] Liu Y,Long A,Chen L,et al. The Asprosin-OLFR734 module regulates appetitive behaviors[J]. Cell Discov,2020,6:19.

[17] Mishra I,Xie WR,Bournat JC,et al. Protein tyrosine phosphatase receptor delta serves as the orexigenic asprosin receptor [J]. Cell Metab,2022,34(4):549-563.

[18] Li E,Shan H,Chen L,et al. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin[J]. Cell Metab,2019,30(2):319-328.e8.

[19] Jung TW,Kim HC,Kim HU,et al. Asprosin attenuates insulin signaling pathway through PKC delta-activated ER stress and inflammation in skeletal muscle[J]. J Cell Physiol,2019,234(11):20888-20899.

[20] Naiemian S,Naeemipour M,Zarei M,et al. Serum concentration of asprosin in new-onset type 2 diabetes[J]. Diabetol Metab Syndr,2020,12:65.

[21] Alobaidi MBA,Al-Samarrai RRH. Correlation between serum asprosin level and oxidative stress in Iraqi patients with type ii diabetes mellitus[J].Systematic Reviews in Pharmacy,2020,11(12):1729-1733.

[22] Xu X,Luo Z,He Y,et al. Application of untargeted lipidomics based on UHPLC-high resolution tandem MS analysis to profile the lipid metabolic disturbances in the heart of diabetic cardiomyopathy mice[J]. J Pharm Biomed Anal,2020,190:113525.

[23] Matsuura TR,Leone TC,Kelly DP. Fueling Cardiac Hypertrophy[J]. Circ Res,2020,126(2):197-199.

[24] Nirengi S,Peres Valgas Da Silva C,Stanford KI. Disruption of energy utilization in diabetic cardiomyopathy; a mini review[J]. Curr Opin Pharmacol,2020,54:82-90.

[25] Tang SG,Liu XY,Ye JM,et al. Isosteviol ameliorates diabetic cardiomyopathy in rats by inhibiting ERK and NF-κB signaling pathways[J]. J Endocrinol,2018,238(1):47-60.

[26] Zhang Z,Tan Y,Zhu L,et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway[J]. Life Sci,2019,231:116554.

[27] Mingshien W,Chaoyung W,Jihkai Y,et al. The role of Asprosin in patients with dilated cardiomyopathy[J]. BMC Cardiovasc Disord,2020,20(1):402.

[28] Poredos P,Spirkoska A,Lezaic L,et al. Patients with an Inflamed Atherosclerotic Plaque have Increased Levels of Circulating Inflammatory Markers[J]. J Atheroscler Thromb,2017,24(1):39-46.

[29] 尹建红,刘鸣,孙莉,等. 山西省长治市社区老年2型糖尿病患者血清白脂素对颈动脉粥样硬化的风险评估[J]. 中华糖尿病杂志,2022,14(03):253-259.

[30] You M,Liu YS,Wang BW,et al. Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease[J]. Cardiovasc Diabetol,2022,21(1):25.

[31] Chen S,Wang X,Qiu CM,et al. Study of the Role and Mechanism of Asprosin/Spartin Pathway in Cardiac Microvascular Endothelial Injury Induced by Diabete Mellitus[J]. Sichuan Da Xue Xue Bao Yi Xue Ban,2019,50(6):827-834.

[32] Zou J,Xu C,Zhao Z,et al. Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway[J]. J Transl Med,2022,20(1):337.

[33] Wu S,Wu F,Ding Y,et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events:A systematic review and meta-analysis[J]. Sci Rep,2016,6:33386.

[34] Targher G,Byrne CD,Lonardo A,et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J]. J Hepatol,2016,65(3):589-600.

[35] Jaruvongvanich V,Wirunsawanya K,Sanguankeo A,et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification:A systematic review and meta-analysis[J]. Dig Liver Dis,2016,48(12):1410-1417.

[36] Keskin M,Hay?ro?lu M?,Uzun AO,et al. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction [J]. Am J Cardiol,2017,120(10):1720-1726.

[37] Stahl EP,Dhindsa DS,Lee SK,et al. Nonalcoholic Fatty Liver Disease and?the?Heart:JACC State-of-the-Art Review[J]. J Am Coll Cardiol,2019,73(8):948-963.

[38] Cai J,Zhang XJ,Ji YX,et al. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases[J]. Circ Res,2020,126(5):679-704.

[39] Acara AC,Bolatkale M,K?z?lo?lu ?,et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris:Asprosin[J]. Am J Emerg Med,2018,36(8):1504-1505.

[40] Moradi N,Fouani FZ,Vatannejad A,et al. Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD):a case-control study[J]. Lipids Health Dis,2021,20(1):88.

相似文献/References:

[1]陈炜,许贞蓉.表观遗传学与代谢性心血管疾病的研究进展[J].心血管病学进展,2019,(6):902.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.016]
　CHEN Wei,XU Zhenrong.Epigenetics and Cardiometabolic Disease[J].Advances in Cardiovascular Diseases,2019,(8):902.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.016]
[2]林力 陈敏 梁明露 宁璐璐 王紫 黄恺.非编码RNA在代谢性心血管疾病中的研究及治疗现状[J].心血管病学进展,2022,(10):915.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.012]
　LIN Li,CHEN Min,LIANG Minglu,et al.Research and Treatment Status of Non-coding RNA in Metabolic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(8):915.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.012]

更新日期/Last Update: 2023-09-21